CD7 and neoplasm: Intravenous injection of anti-CD7 F(ab′)2 did not modulate T-cell functionality in vivo and tumor rejection was unaffected, making CD7 a promising target for inert and non-invasive T-cell tracking across the immunotherapeutic spectrum.